Abstract
Androgen therapy may be divided into physiological and pharmacological applications. The pharmacological applications usually involve non-physiological doses of synthetic androgens as second-line, empirical treatment where more specific medical therapy is not yet available. The physiological applications consist of androgen replacement therapy, the treatment of androgen deficiency in hypogonadal men. Androgen replacement therapy aims to replicate physiological actions of endogenous testosterone by steadily maintaining physiological blood levels of testosterone. Since the underlying disorders are virtually always irreversible, this requires life-long administration of testosterone, making it desirable that the testosterone formulations be long-acting. Reliable therapeutic compliance over the lifetime of the patient depends heavily on a convenient formulation which ensures the continuity of treatment. The pharmacological properties of testosterone, notably its rapid hepatic metabolism and very low oral bioavailability, dictate the need for development of depot, sustained-release testosterone formulations (Parkes 1938; Wilson 1980). The perfect depot would be safe, effective, inexpensive, convenient, and long-acting with a reproducible, zero-order release profile. Not surprisingly, even six decades after entry of testosterone into clinical use (Foss 1939; Hamilton 1937), this ideal has not been achieved. Nevertheless one of the oldest testosterone formulations, the subdermal testosterone implant, provides a very close approximation to this ideal in providing stable blood testosterone levels lasting 4–6 months after a single implantation. Curiously this cheap, safe and effective treatment modality was neglected for decades despite its many advantages for androgen replacement therapy but is now undergoing a revival of interest, particularly since its desirable pharmacological properties have been outlined (Cantrill et al. 1984; Conway et al. 1988; Handelsman et al. 1990, 1997; Jockenhövel et al. 1996; Nieschlag 1996; Zacharin and Warne 1997).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anderson DC (1974) Sex hormone binding globulin. Clin Endocrinol 3: 69–96
Behre HM, Nieschlag E (1998) Comparative pharmacokinetics of androgen preparations: application of computer analysis and simulation. In: Nieschlag E, Behre HM (eds) Testosterone: Action Deficiency Substitution. Springer-Verlag, Berlin, pp 329–348
Bishop PMF, Folley SJ (1951) Absorption of hormone implants. Lancet ii: 229 - 232
Burris AS, Ewing LL, Sherins RJ (1988) Initial trial of slow-release testosterone microspheres in hypogonadal men. Fertil Steril 50: 493 - 497
Butenandt A, Hanisch G (1935) Über die Umwandlung des Dehydroandrosterons in Andro- stenol-(17)-one-(3) (Testosterone); Umweg zur Darstellung des Testosterons aus Cholsterin (vorläufige Mitteilung). Z Physiol Chem 237: 89–97
Cantrill JA, Dewis P, Large DM, Newman M, Anderson DC (1984) Which testosterone replacement therapy? Clin Endocrinol 24: 97–107
Conway AJ, Boylan LM, Howe C, Ross G, Handelsman DJ (1988) A randomised clinical trial of testosterone replacement therapy in hypogonadal men. Int J Androl 11: 247–264
David K, Dingmanse E, Freud J, Lacqueur E (1935) Über krystallinisches männliches Hormon aus Hoden ( Testosteron), wirksamer als aus Harn oder aus Cholestrin bereitetes Androsteron. Z Physiol Chem 233: 281–282
Deansley R, Parkes AS (1937) Factors influencing effectiveness of administered hormones. Proc Royal Soc Lond 124: 279–98
Deansley R, Parkes AS (1938) Further experiments on the administration of hormones by the subcutaneous implantation of tablets. Lancet ii: 606–608
Dewis P, Newman M, Ratcliffe WA, Anderson DC (1986) Does testosterone affect the normal menstrual cycle? Clin Endocrinol 24: 515–521
Diaz-Sanchez V, Garza-Flores J, Larrea F, Richards E, Ulloa-Aguirre A, Veayra F (1989) Absorption of dihydrotestosterone ( DHT) after its intramuscular administration. Fert Steril 51: 493–497
Emmens W (1941) Rate of absorption of androgens and estrogens in free and esterified form from subcutaneously implanted pellets. Endocrinology 28: 633–642
Forbes TR (1941) Absorption of pellets of crystalline testosterone, testosterone propionate, methyl testosterone, progesterone, desoxycorticosterone and stilbestrol implanted in the rat. Endocrinology 32: 70–76
Foss GL (1939) Clinical administration of androgens. Lancet i: 502–504
Frey H, Aakvag A, Saanum D, Falch J (1979) Bioavailability of testosterone in males. Eur J Clin Pharmacol 16: 345–349
Gandy HM (1977) Androgens. In: Fuchs F, Klopper A (eds) Endocrinology of Pregnancy. Harper & Row, Hagerstown, Maryland, pp 123–156
Gardner FH, Besa EC (1983) Physiologic mechanisms and the hematopoietic effects of the androstanes and their derivatives. Curr Top Hematol 4: 123–195
Hamilton JB (1937) Treatment of sexual underdevelopment with synthetic male hormone substance. Endocrinology 21: 649–654
Hamilton JB, Dorfman RI (1939) Influence of the vehicle upon the length and strength of the action of male hormone substance, testosterone propionate. Endocrinology 24: 711–719
Handelsman DJ, Conway AJ, Boylan LM (1990) Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 71: 216–222
Handelsman DJ, Conway AJ, Boylan LM (1992) Suppression of human spermatogenesis by testosterone implants in man. J Clin Endocrinol Metab 75: 1326–1332
Handelsman DJ, Conway AJ, Howe CJ, Turner L, Mackey MA (1996) Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. J Clin Endocrinol Metab 81: 4113–4121
Handelsman DJ, Mackey MA, Howe C, Turner L, Conway AJ (1997) Analysis of testosterone implants for androgen replacement therapy. Clin Endocrinol 47: 311–316
Hellman L, Bradlow HL, Frazell EL, Gallagher TF (1956) Tracer studies of the absorption and fate of steroid hormones in man. J Clin Invest 35: 1033–1044
Howard JE, Vest SA (1939) Clinical experiments with male sex hormones. II Further observations on testosterone propionate in adult hypogonadism, and preliminary report on the implantation of testosterone. Am J Med Sci 198: 823–837
Jockenhövel F, Vogel E, Kreutzer M, Reinhardt W, Lederbogen S, Reinwein D (1996) Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogo-nadal men. Clin Endocrinol 45: 61–71
Kochakian CD (ed) (1976). Anabolic-Androgenic Steroids. Handbook of Experimental Pharmacology. Berlin, Springer-Verlag
Loeser AA (1940) Subcutaneous implantation of female and male hormone in tablet form in women. Br J Med: 479–482
Mooradian AD, Morley JE, Korenman SG (1987) Biological actions of androgens. Endo Rev 8: 1–28
Nieschlag E (1996) Testosterone replacement therapy - something old, something new. Eur J Endocrinol 45: 261–262
Nieschlag E, Cuppers HJ, Wickings EJ (1977) Influence of sex, testicular development and liver function on the bioavailability of oral testosterone. Eur J Clin Invest 7: 145–147
Nieschlag E, Mauss J, Coert A, Kicovic P (1975) Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinol 79: 366–374
Parkes AS (1938) Effective absorption of hormones. Br J Med: 371–373
Petra P, Stanczyk FZ, Namkung PC, Fritz MA, Novy ML (1985) Direct effect of sex-steroid binding protein ( SBP) of plasma on the metabolic clearance rate of testosterone in the rhesus macaque. J Steroid Biochem Molec Biol 22: 739–746
Reiter T (1963) Testosterone implantation: a clinical study of 240 implantations in ageing males. J Am Geriat Soc 11: 54–50
Ruzicka L, Wettstein A (1935) Über die krystallische Herstellung des Testikelhormons, Testosteron (androsten-3-on-17-ol). Helv Chim Acta 18: 1264–1275
Southren AL, Gordon GG, Tochimoto S (1968) Further studies of factors affecting metabolic clearance rate of testosterone in man. J Clin Endocrinol Metab 28: 1105–1112
Swyer GIM (1953) Effects of testosterone implants in men with defective spermatogenesis. Br J Med: 1080–1081
Thorn MH, Collins WP, Studd J WW (1981) Hormonal profiles in postmenopausal women after therapy with subcutaneous implants. Br J Obstet Gynaecol 88: 426–433
Thorn GW, Firor WM (1940) Desoxycorticosterone acetate therapy in Addisons disease. J Am Med Assoc 114: 2517–2525
Vest SA, Howard JE (1939) Clinical experiments with androgens IV a method of implantation of crystalline testosterone. J Am Med Assoc 113: 1869–1872
von Schoultz B, Carlstrom K (1989) On the regulation of sex-hormone-binding globulin. A challenge of an old dogma and outlines of an alternative mechanism. J Steroid Biochem Molec Biol 32: 327–334
Wilson JD (1980) The use and misuse of androgens. Metabolism 29: 1278–1295
Zacharin MR, Warne GL (1997) Treatment of hypogonadal adolescent boys with long acting subcutaneous testosterone pellets. Arch Dis Child (in press)
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Handelsman, D.J. (1998). Clinical pharmacology of testosterone pellet implants. In: Nieschlag, E., Behre, H.M. (eds) Testosterone. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72185-4_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-72185-4_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-72187-8
Online ISBN: 978-3-642-72185-4
eBook Packages: Springer Book Archive